Literature DB >> 7829239

Cancer in patients with ulcerative colitis.

L Mellemkjaer1, J H Olsen, M Frisch, C Johansen, G Gridley, J K McLaughlin.   

Abstract

A cohort of 5,546 ulcerative colitis patients was identified from the Danish Hospital Discharge Register for 1977-1989. Patients not included in the cohort comprised those with proctitis, those treated in outpatient clinics and those for whom follow-up was less than 1 year. The cohort was linked to the Danish Cancer Registry in order to assess the risks for colorectal and other cancers. The linkage revealed a significant increase in the number of colorectal cancers over that in the general population (RR = 1.8; n = 42; 95% CI = 1.3-2.4) with consistent relative risks during early and late follow-up. The relative risk was considerably higher among younger (20-39 years: RR = 22; n = 8; 95% CI = 9.7-44) than older patients (> or = 60 years: RR = 1.3; n = 25; 95% CI = 0.8-1.9), but the risk difference between patients and the general population was approximately constant across all ages. In addition, we observed a significant increase in the relative risk of hepatobiliary cancers (RR = 2.3; n = 9; 95% = 1.0-4.3) and a slight but significant increase in the relative risk of non-melanoma skin cancer (RR = 1.4; n = 37; 95% CI = 1.0-1.9). In summary, our population-based study confirms the increased risk of colorectal cancer among patients with ulcerative colitis and provides new leads suggesting that hepatobiliary cancer and non-melanoma skin cancer should be considered as possible sites for future patient monitoring.

Entities:  

Mesh:

Year:  1995        PMID: 7829239     DOI: 10.1002/ijc.2910600309

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Involvement of activation-induced cytidine deaminase in the development of colitis-associated colorectal cancers.

Authors:  Yoko Endo; Hiroyuki Marusawa; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2010-09-28       Impact factor: 7.527

Review 3.  Risk of cancer in ulcerative colitis.

Authors:  A Ekbom
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 4.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

5.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 6.  Nonmelanoma skin cancer in inflammatory bowel disease: a review.

Authors:  Millie D Long; Michael D Kappelman; Clare A Pipkin
Journal:  Inflamm Bowel Dis       Date:  2010-11-04       Impact factor: 5.325

7.  Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.

Authors:  Millie D Long; Hans H Herfarth; Clare A Pipkin; Carol Q Porter; Robert S Sandler; Michael D Kappelman
Journal:  Clin Gastroenterol Hepatol       Date:  2010-01-16       Impact factor: 11.382

Review 8.  Colorectal cancer in inflammatory bowel disease: review of the evidence.

Authors:  D S Keller; A Windsor; R Cohen; M Chand
Journal:  Tech Coloproctol       Date:  2019-01-30       Impact factor: 3.781

Review 9.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Prevalence of gastrointestinal diseases in two British national birth cohorts.

Authors:  A G C Ehlin; S M Montgomery; A Ekbom; R E Pounder; A J Wakefield
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.